Theravance Biopharma, Inc. (TBPH) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TBPH currently has 51.3M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 5.94% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 07, 2026 |
10-Q filing | 51.3M shares outstanding |
51M | 0 |
| Mar 23, 2026 |
10-K filing | 51.5M shares outstanding |
52M | 0 |
| Nov 12, 2025 |
10-Q filing | 50.5M shares outstanding |
51M | 0 |
| Aug 13, 2025 |
10-Q filing | 50.2M shares outstanding |
50M | 0 |
| May 12, 2025 |
10-Q filing | 49.7M shares outstanding |
50M | 0 |
| Mar 07, 2025 |
10-K filing | 48.8M shares outstanding |
49M | 0 |
| Nov 14, 2024 |
10-Q filing | 49.0M shares outstanding |
49M | 0 |
| Aug 08, 2024 |
10-Q filing | 48.7M shares outstanding |
49M | 0 |
| May 15, 2024 |
10-Q filing | 48.3M shares outstanding |
48M | 0 |
| Mar 01, 2024 |
10-K filing | 65.2M shares outstanding |
65M | 0 |
| Nov 09, 2023 |
10-Q filing | 65.2M shares outstanding |
65M | 0 |
| Aug 09, 2023 |
10-Q filing | 65.2M shares outstanding |
65M | 0 |
| May 10, 2023 |
10-Q filing | 62.9M shares outstanding |
63M | 0 |
| Mar 01, 2023 |
10-K filing | 73.6M shares outstanding |
74M | 0 |
| Nov 09, 2022 |
10-Q filing | 75.5M shares outstanding |
76M | 0 |
| Sep 20, 2022 |
8-K filing: Theravance Biopharma, Inc. closed a transaction to purchase 9,644,807 ordinary shares from GSK Finance (No.3) plc on September 20, 2022, as per the Share Repurchase Agreement dated September 16, 2022. |
76M | 0 |
| Sep 19, 2022 |
8-K filing: Theravance Biopharma, Inc. entered into a share repurchase agreement to purchase 9,644,807 ordinary shares from GSK Finance (No.3) plc at a price of $9.75 per share, resulting in a total consideration of $94,036,868.25. ($94.04M proceeds) |
76M | 0 |
| Aug 08, 2022 |
10-Q filing | 76.3M shares outstanding |
76M | 0 |
| May 06, 2022 |
10-Q filing | 75.2M shares outstanding |
75M | 0 |
| Feb 28, 2022 |
10-K filing | 69.5M shares outstanding |
69M | 0 |
| Nov 08, 2021 |
10-Q filing | 64.3M shares outstanding |
64M | 0 |
| Aug 05, 2021 |
10-Q filing | 73.5M shares outstanding |
73M | 0 |
| Jun 28, 2021 |
8-K filing: Theravance Biopharma, Inc. entered into an underwriting agreement for a public offering of 6,700,000 ordinary shares at $15.00 per share, with an option for the underwriters to purchase an additional 1,005,000 ordinary shares. |
65M | 0 |
| May 06, 2021 |
10-Q filing | 64.7M shares outstanding |
65M | 0 |
| Feb 26, 2021 |
10-K filing | 62.8M shares outstanding |
63M | 0 |
| Nov 09, 2020 |
10-Q filing | 63.7M shares outstanding |
64M | 0 |
| Aug 10, 2020 |
10-Q filing | 63.3M shares outstanding |
63M | 0 |
| May 08, 2020 |
10-Q filing | 60.1M shares outstanding |
60M | 0 |
| Feb 27, 2020 |
10-K filing | 56.5M shares outstanding |
56M | 0 |
| Feb 13, 2020 |
8-K filing: Theravance Biopharma, Inc. entered into an underwriting agreement for a public offering of 5,500,000 ordinary shares at $27.00 per share, with an option for the underwriters to purchase up to an additional 825,000 shares. |
N/A | 0 |